These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 18829967)

  • 1. Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5.
    Paoletti P; Vila I; Rifé M; Lizcano JM; Alberch J; Ginés S
    J Neurosci; 2008 Oct; 28(40):10090-101. PubMed ID: 18829967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-Dependent Kinase 5 Dysfunction Contributes to Depressive-like Behaviors in Huntington's Disease by Altering the DARPP-32 Phosphorylation Status in the Nucleus Accumbens.
    Brito V; Giralt A; Masana M; Royes A; Espina M; Sieiro E; Alberch J; Castañé A; Girault JA; Ginés S
    Biol Psychiatry; 2019 Aug; 86(3):196-207. PubMed ID: 31060804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreasing Levels of the cdk5 Activators, p25 and p35, Reduces Excitotoxicity in Striatal Neurons.
    Park KH; Lu G; Fan J; Raymond LA; Leavitt BR
    J Huntingtons Dis; 2012; 1(1):89-96. PubMed ID: 24353748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylation of huntingtin by cyclin-dependent kinase 5 is induced by DNA damage and regulates wild-type and mutant huntingtin toxicity in neurons.
    Anne SL; Saudou F; Humbert S
    J Neurosci; 2007 Jul; 27(27):7318-28. PubMed ID: 17611284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2.
    Smith PD; Mount MP; Shree R; Callaghan S; Slack RS; Anisman H; Vincent I; Wang X; Mao Z; Park DS
    J Neurosci; 2006 Jan; 26(2):440-7. PubMed ID: 16407541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.
    Tang TS; Chen X; Liu J; Bezprozvanny I
    J Neurosci; 2007 Jul; 27(30):7899-910. PubMed ID: 17652581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies.
    Brito V; Puigdellívol M; Giralt A; del Toro D; Alberch J; Ginés S
    Cell Death Dis; 2013 Apr; 4(4):e595. PubMed ID: 23598407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells.
    Gines S; Ivanova E; Seong IS; Saura CA; MacDonald ME
    J Biol Chem; 2003 Dec; 278(50):50514-22. PubMed ID: 14522959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cdk5-mediated mitochondrial fission: A key player in dopaminergic toxicity in Huntington's disease.
    Cherubini M; Puigdellívol M; Alberch J; Ginés S
    Biochim Biophys Acta; 2015 Oct; 1852(10 Pt A):2145-60. PubMed ID: 26143143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington's disease.
    Ribeiro FM; Paquet M; Ferreira LT; Cregan T; Swan P; Cregan SP; Ferguson SS
    J Neurosci; 2010 Jan; 30(1):316-24. PubMed ID: 20053912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells.
    Xifró X; García-Martínez JM; Del Toro D; Alberch J; Pérez-Navarro E
    J Neurochem; 2008 Jun; 105(5):1596-612. PubMed ID: 18221365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease.
    Park KHJ; Franciosi S; Parrant K; Lu G; Leavitt BR
    Neuroscience; 2017 Jun; 352():79-87. PubMed ID: 28391013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of aberrant cyclin-dependent kinase 5/p25 activity in experimental traumatic brain injury.
    Yousuf MA; Tan C; Torres-Altoro MI; Lu FM; Plautz E; Zhang S; Takahashi M; Hernandez A; Kernie SG; Plattner F; Bibb JA
    J Neurochem; 2016 Jul; 138(2):317-27. PubMed ID: 26998748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation.
    Charvin D; Vanhoutte P; Pagès C; Borrelli E; Caboche J
    Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12218-23. PubMed ID: 16103364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of calpain/p35-p25/Cdk5/NMDAR signaling pathway in glutamate-induced neurotoxicity in cultured rat retinal neurons.
    Miao Y; Dong LD; Chen J; Hu XC; Yang XL; Wang Z
    PLoS One; 2012; 7(8):e42318. PubMed ID: 22870316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striatal dysregulation of Cdk5 alters locomotor responses to cocaine, motor learning, and dendritic morphology.
    Meyer DA; Richer E; Benkovic SA; Hayashi K; Kansy JW; Hale CF; Moy LY; Kim Y; O'Callaghan JP; Tsai LH; Greengard P; Nairn AC; Cowan CW; Miller DB; Antich P; Bibb JA
    Proc Natl Acad Sci U S A; 2008 Nov; 105(47):18561-6. PubMed ID: 19017804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of calpain-dependent cleavage of the CDK5 activator p35 to p25 by site-specific phosphorylation.
    Kamei H; Saito T; Ozawa M; Fujita Y; Asada A; Bibb JA; Saido TC; Sorimachi H; Hisanaga S
    J Biol Chem; 2007 Jan; 282(3):1687-94. PubMed ID: 17121855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.
    Saavedra A; Giralt A; Rué L; Xifró X; Xu J; Ortega Z; Lucas JJ; Lombroso PJ; Alberch J; Pérez-Navarro E
    J Neurosci; 2011 Jun; 31(22):8150-62. PubMed ID: 21632937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of CDK5/P25 formation/inhibition in neurodegeneration.
    Camins A; Verdaguer E; Folch J; Canudas AM; Pallàs M
    Drug News Perspect; 2006 Oct; 19(8):453-60. PubMed ID: 17160145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator.
    Hisanaga S; Saito T
    Neurosignals; 2003; 12(4-5):221-9. PubMed ID: 14673209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.